Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064798 · ClinicalTrials.gov registry record · NA
Cryocompression for CIPN
A NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07064798: Recruiting NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Dana-Farber Cancer Institute.
NCT07064798 is a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07064798, a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and/or loss of motor function, that may occur as a result of taxane-based chemotherapy. The name of the device used in this research study is: -Paxman Limb Cryocompression System (PLCS)
Primary Outcome
Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy module (EORTC QLQ-CIPN20). This aim is defined as evaluating the incidence and severity of subjectively reported CIPN symptoms, including numbness, tingling, and pain in hands and feet. Clinically significant CIPN is expected to emerge during taxane-based treatment and will be cap
Conditions Studied
Interventions
- DEVICE Paxman Limb Cryocompression System
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT07064798 shows while recruiting
NCT07064798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Paxman Limb Cryocompression System is the first listed.
NCT07064798 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07064798 about?
NCT07064798 is a clinical study titled "Cryocompression for CIPN". This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and/or loss of motor function, t...
What is the current status of trial NCT07064798?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-10-22. Estimated completion is 2027-08.
What conditions does trial NCT07064798 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Taxane-Induced Peripheral Neuropathy.
What interventions are being tested in trial NCT07064798?
The interventions under investigation include: Paxman Limb Cryocompression System (DEVICE).
Who is sponsoring clinical trial NCT07064798?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064798 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07064798's enrollment target sits among peer trials
50 14th of 29 higher than 15 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
RECRUITING · NA
-
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI